(VIANEWS) – IBA (IBAB.BR), SANOFI (SAN.PA), ABEO (ABEO.PA) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio at the moment. The payout ratio in itself isn’t a promise of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.
When researching a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. IBA (IBAB.BR)
94.67% Payout Ratio
Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
Earnings Per Share
As for profitability, IBA has a trailing twelve months EPS of €-0.31.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -21.17%.
Volume
Today’s last reported volume for IBA is 19497 which is 61.88% below its average volume of 51157.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jun 29, 2023, the estimated forward annual dividend rate is 0.21 and the estimated forward annual dividend yield is 1.69%.
Moving Average
IBA’s value is way above its 50-day moving average of €10.50 and way higher than its 200-day moving average of €11.40.
Revenue Growth
Year-on-year quarterly revenue growth grew by 5.9%, now sitting on 370.66M for the twelve trailing months.
More news about IBA.
2. SANOFI (SAN.PA)
82.79% Payout Ratio
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €4.3.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 21.15. Meaning, the purchaser of the share is investing €21.15 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.27%.
Sales Growth
SANOFI’s sales growth for the current quarter is 5.7%.
Yearly Top and Bottom Value
SANOFI’s stock is valued at €90.96 at 17:10 EST, way below its 52-week high of €105.18 and way above its 52-week low of €80.60.
More news about SANOFI.
3. ABEO (ABEO.PA)
65.74% Payout Ratio
Abéo SA engages in the design, manufacture, and distribution of sports and leisure equipment in France and internationally. It offers gymnastics equipment and facilities, gym mats, team sports equipment, physical education, trampoline parks, and artificial climbing walls, as well as changing room layouts, cabins, cupboards, and lockers. It offers its products under the GYMNOVA, JANSSEN-FRITSEN, SPIETH GYMNASTICS, SCHELDE SPORTS, SPIETH AMERICA, SPORTSAFE, ERHARD SPORT, ADEC SPORT, O'JUMP, CANNICE, BOSAN, PCV, VOGOSCOPE, BIGAIRBAG, BRICK, EP, CLIP'N CLIMB, TOP30, DOCK 39, FUN SPOT, CLIMBAT, FRANCE EQUIPEMENT, META, PROSPEC, NAVIC, SANITEC, SUFFIXE, and SANELITE brands. The company was founded in 1955 and is headquartered in Rioz, France.
Earnings Per Share
As for profitability, ABEO has a trailing twelve months EPS of €0.5.
PE Ratio
ABEO has a trailing twelve months price to earnings ratio of 22.3. Meaning, the purchaser of the share is investing €22.3 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.15%.
Yearly Top and Bottom Value
ABEO’s stock is valued at €11.15 at 17:10 EST, way under its 52-week low of €12.90.
Volume
Today’s last reported volume for ABEO is 367 which is 65.5% below its average volume of 1064.
Moving Average
ABEO’s worth is way under its 50-day moving average of €14.04 and way under its 200-day moving average of €15.78.
More news about ABEO.
4. QUADIENT (QDT.PA)
30.51% Payout Ratio
Quadient S.A. provides intelligent communication automation, mail-related, and parcel locker solutions for customers through digital and physical channels in North America, France, Benelux, the United Kingdom, Ireland and Germany, Austria, Italy, Switzerland, and internationally. It provides Quadient Inspire, a software solution that facilitates the creation and management of transactional and marketing communication documents, as well as manages omnichannel delivery for the communications; Quadient Impress, a cloud-based software that facilitates outbound document automation; YayPay, account receivable process automation solutions; and Beanworks, an accounts payable automation software solution. The company also offers Quadient Inspire Flex, which enables organizations to create and deliver personalized, compliant customer communications across various channels from one centralized platform; Quadient DigitalBOOST, a suite of pre-packaged solutions that digitalizes customer processes and contracts; and Quadient Inspire Journey, a cloud-based journey mapping solution that integrates customer journey mapping, data, and communications technologies. In addition, it supplies software, equipment, and services for managing incoming and outgoing mails; and provides hardware and software platform that facilitates invoicing and customer communications, multi-channel mail processing, last-mile parcel delivery, and the consolidation of their return. Further, the company operates a pick-up, drop-off solution that offers businesses and people who need to manage their deliveries and returns. It serves financial services, healthcare, higher education, insurance, and retail industries, as well as service providers industries. The company was formerly known as Neopost S.A. and changed its name to Quadient S.A. in September 2019. Quadient S.A. was founded in 1924 and is headquartered in Bagneux, France.
Earnings Per Share
As for profitability, QUADIENT has a trailing twelve months EPS of €2.4.
PE Ratio
QUADIENT has a trailing twelve months price to earnings ratio of 7.94. Meaning, the purchaser of the share is investing €7.94 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.07%.
Volume
Today’s last reported volume for QUADIENT is 34788 which is 17.21% above its average volume of 29678.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Aug 3, 2023, the estimated forward annual dividend rate is 0.6 and the estimated forward annual dividend yield is 3.13%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 0.3%, now sitting on 1.08B for the twelve trailing months.
Moving Average
QUADIENT’s worth is under its 50-day moving average of €19.47 and below its 200-day moving average of €19.32.
More news about QUADIENT.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of €1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing €1 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Volume
Today’s last reported volume for 1 is 1 which is 1% above its average volume of 1.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jan 1, 1970, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 1%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 1% and 1%, respectively.
Volatility
1’s last week, last month’s, and last quarter’s current intraday variation average was 1.00%, 1.00%, and 1.00%.
1’s highest amplitude of average volatility was 1.00% (last week), 1.00% (last month), and 1.00% (last quarter).
More news about 1.
